Development of Chitosan-SLN Microparticles for chemotherapy: In vitro approach through efflux-transporter modulation

Journal of Controlled Release

Volumn 131, Issue 3, 2008, Pages 190-197

  Dharmala, Kiran ^a   Yoo, Jin Wook ^a   Lee, Chi H ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Chitosan; Core shell particle; Formulation; Microparticle; Pulmonary delivery

Indexed keywords

ACIDS; CARBOXYLIC ACIDS; CHEMOTHERAPY; CHITIN; CHITOSAN; DRUG DELIVERY; DRUG PRODUCTS; ESTERS; MODULATION; NANOSTRUCTURED MATERIALS; POLYMER BLENDS; STEARIC ACID; SUBSTRATES;

ABC TRANSPORTERS; ANTI-CANCER DRUGS; BURST RELEASES; CORE SHELL PARTICLE; DRUG DELIVERY SYSTEMS; EFFICIENT DRUG DELIVERIES; EFFLUX TRANSPORTERS; FORMULATION; IN VITRO; ISOTHIOCYANATE; MICROPARTICLE; MICROPARTICLES; NIFEDIPINE; PULMONARY DELIVERY; RELEASE PROFILES; SOLID LIPID NANOPARTICLES; SUSTAINED RELEASES; TAMOXIFEN; TARGET SITES; UPTAKE RATES; VERAPAMIL;

AMINES;

ABC TRANSPORTER; CHITOSAN; DRUG CARRIER; NIFEDIPINE; PHENETHYL ISOTHIOCYANATE; SOLID LIPID NANOPARTICLE; STEARIC ACID; TAMOXIFEN; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; HUMAN; HUMAN CELL; PARTICLE SIZE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHITOSAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG THERAPY; ISOTHIOCYANATES; LIPIDS; NANOPARTICLES; NIFEDIPINE; PARTICLE SIZE; TAMOXIFEN; VERAPAMIL;

EID: 54149090413     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.07.034     Document Type: Article

References (51)

1. Tsuruo T., Iida H., Tsukagoshi S., and Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41 5 (1981) 1967-1972
2. Daenen S., van der Holt B., Verhoef G.E., Lowenberg B., Wijermans P.W., Huijgens P.C., et al. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. Leuk. Res. 28 10 (2004) 1057-1067
3. HO E.A., Lim S.P., Christine A., and Micheline P.M. Localized delivery of chemotherapeutic agents may improve current treatment strategies for ovarian cancer. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J. Control. Release 117 1 (2007) 20-27
4. Taylor C.W., Dalton W.S., Mosley K., Dorr R.T., and Salmon S.E. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Res. Treat. 42 1 (1997) 7-14
5. Xu C., Li C.Y., and Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28 3 (2005) 249-268
6. Bhavsar M.D., Tiwari S.B., and Amiji M.M. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J. Control. Release 110 2 (2006) 422-430
7. Soppimath K.S., Tan D.C., and Yang Y.Y. pH-triggered thermally responsive polymer core-shell nanoparticles for drug delivery. Adv. Mater. 17 3 (2005) 318-323
8. Cao S., Liu B., Deng X., and Li S. Core/shell particles containing 3-(methacryloxypropyl)-trimethoxysilane in the shell: synthesis, characterization, and application. Macromol. Biosci. 5 7 (2005) 669-676
9. Koennings S., Berie A., Tessmar J., and Blunk T. A. Goepferich: influence of wettability and surface activity on release behavior of hydrophilic substances from lipid matrices. J. Control. Release 119 2 (2007) 173-181
10. Lamprecht A., Schafer U., and Lehr C.M. Structural analysis of microparticles by confocal laser scanning microscopy. AAPS PharmSciTech 1 3 (2000) E17
11. D'Souza S.S., and DeLuca P.P. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm. Res. 23 3 (2006) 460-474
12. Chung F.L., Jiao D., Getahun S.M., and Yu M.C. A urinary biomarker for uptake of dietary isothiocyanates in humans. Cancer Epidemiol. Biomark. Prev. 7 2 (1998) 103-108
13. Fowke J.H., Chung F.L., Jin F., Qi D., Cai Q., Conaway C., et al. Urinary isothiocyanate levels, brassica, and human breast cancer. Cancer Res. 63 14 (2003) 3980-3986
14. Berridge M.V., and Tan A.S. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303 2 (1993) 474-482
15. Cory A.H., Owen T.C., Barltrop J.A., and Cory J.G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3 7 (1991) 207-212
16. Eliaz R.E., and Szoka Jr. F.C. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 61 6 (2001) 2592-2601
17. Muvaffak A., Gurhan I., and Hasirci N. Prolonged cytotoxic effect of colchicine released from biodegradable microspheres. J. Biomed. Mater. Res. 71 2 (2004) 295-304
18. Hu K., and Morris M.E. Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J. Pharm. Sci. 93 7 (2005) 1901-1911
19. Ji Y., and Morris M.E. Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochem. Pharmacol. 21 12 (2005) 2261-2269
20. Corrigan O.I., and Heelan B.A. Characterization of drug release from diltiazem-loaded polylactide microspheres prepared using sodium caseinate and whey protein as emulsifying agents. J. Microencapsul 18 3 (2001) 335-345
21. Florea B.I., van der Sandt I.C., Schrier S.M., Kooiman K., Deryckere K., de Boer A.G., et al. Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3). Br. J. Pharmacol. 134 7 (2001) 1555-1563
22. Hamilton K.O., Topp E., Makagiansar I., Siahaan T., Yazdanian M., and Audus K.L. Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J. Pharmacol. Exp. Ther. 298 3 (2001) 1199-1205
23. Hamilton K.O., Backstrom G., Yazdanian M.A., and Audus K.L. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J. Pharm. Sci. 90 5 (2001) 647-658
24. Muller C., Bailly J.D., Jaffrezou J.P., Goubin F., and Laurent G. Pharmacological control of P-glycoprotein expression. Bull. Cancer 81 5 (1994) 386-391
25. Karwatsky J., Lincoln M.C., and Georges E. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry. 42 42 (2003) 12163-12173
26. Kurdziel K.A., Kiesewetter D.O., Carson R.E., Eckelman W.C., and Herscovitch P. Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J. Nucl. Med. 44 8 (2003) 1330-1339
27. Zhang Z., Kleinstreuer C., Kim C.S., and Hickey A.J. Aerosol transport and deposition in a triple bifurcation bronchial airway model with local tumors. Inhal. Toxicol. 14 11 (2002) 1111-1133
28. Dalberg K., Johansson H., Johansson U., and Rutqvist L.E. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery, Stockholm Breast Cancer Study Group. Cancer 82 11 (1998) 2204-2211
29. Naus P.J., Henson R., Bleeker G., Wehbe H., Meng F., and Patel T. Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J. Hepatol. 46 2 (2007) 222-229
30. Lewin J., Cooper A., and Birch B. Progesterone: a novel adjunct to intravesical chemotherapy. BJU Int. 90 7 (2002) 736-741
31. Bilenker J.H., Flaherty K.T., Rosen M., Davis L., Gallagher M., Stevenson J.P., et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin. Cancer Res. 11 4 (2005) 1527-1533
32. Doran A., Obach R.S., Smith B.J., Hosea N.A., Becker S., Callegari E., et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33 1 (2005) 165-174
33. Peng Z.H., Longley P., Zhang C., Borowski Y., Mehlig V., Reddy M., Xia P., Borchard J., Lipman G., Benimetskaya J., Stein L., and C.A. Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy. J. Control. Release 119 2 (2007) 143-152
34. Ferry D.R., Traunecker H., and Kerr D.J. Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer 32A 6 (1996) 1070-1081
35. Hecht S.S. Chemoprevention by isothiocyanates. J. Cell. Biochem., Suppl. 22 (1995) 195-209
36. Hecht S.S. Chemoprevention of lung cancer by isothiocyanates. Adv. Exp. Med. Biol. 401 (1996) 1-11
37. Jakubikova J., Bao Y., and Sedlak J. Isothiocyanates induce cell cycle arrest, apoptosis and mitochondrial potential depolarization in HL-60 and multidrug-resistant cell lines. Anticancer Res. 25 5 (2005) 3375-3386
38. Cavalli R., Caputo O., and Gasco M.R. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci. 10 4 (2000) 305-309
39. Miwa A., Ishibe A., Nakano M., Yamahira T., Itai S., Jinno S., et al. Development of novel chitosan derivatives as micellar carriers of taxol. Pharm. Res. 15 12 (1998) 1844-1850
40. Zheng A.P., Yu S.Y., Zhao Y., and Wu F.L. Preparation and properties of 5-fluorouracil-loaded chitosan microspheres for the intranasal administration. Beijing Da. Xue. Bao. 36(3) (2004) 300-304
41. Jaspart S., Piel G., Delattre L., and Evrard B. Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications. Expert Opin. Drug. Deliv. 2 1 (2005) 75-87
42. Pasparakis G., and Bouropoulos N. Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate-chitosan beads. Int. J. Pharm. 323 1-2 (2006) 34-42
43. Singla A.K., Sharma M.L., and Dhawan S. Nifedipine loaded chitosan microspheres: characterization of internal structure. Biotech. Histochem. 76 4 (2001) 165-171
44. Dhawan S., and Singla A.K. Nifedipine loaded chitosan microspheres prepared by emulsification phase-separation. Biotech. Histochem. 78 5 (2003) 243-254
45. Kishida A., Dressman J., Yoshika S., Aso Y., and Takeda Y. Some determinants of morphology and release rate from polylactic acid microspheres. J. Control. Release 13 1 (1990) 83-89
46. Hamilton K.O., Yazdanian M.A., and Audus K.L. Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands. Int. J. Pharm. 228 1-2 (2001) 171-179
47. Chen Y.R., Han J., Kori R., T Kong A.-N., and Tan T.-H. Phenylethyl Isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase. J. Biol. Chem. 277 42 (2002) 39334-39342
48. Donnenberg VS., Rodney J., and Donnenberg A. Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J. Control. Release 122 3 (2007) 385-391
49. Davda J., and Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 233 1-2 (2002) 51-59
50. Kawabata S., Oka M., Soda H., Shiozawa K., Nakatomi K., Tsurutani J., et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin. Cancer Res. 9 8 (2003) 3052-3057
51. Ikuta K., Takemura K., Sasaki K., Kihara M., Nishimura M., Ueda N., et al. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol. Pharm. Bull. 28 4 (2005) 707-712